The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.175
Bid: 0.17
Ask: 0.18
Change: -0.01 (-5.41%)
Spread: 0.01 (5.882%)
Open: 0.185
High: 0.00
Low: 0.00
Prev. Close: 0.185
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

16 Sep 2021 12:47

RNS Number : 0420M
Nuformix PLC
16 September 2021
 

16 September 2021

Nuformix plc

 

("Nuformix" or the "the Company")

  

Director/PDMR Shareholding

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that today the Company received notice that Dr Alastair Riddell, Chairman of the Company, purchased 350,000 ordinary shares of 0.1 pence each ("Ordinary Shares") at a price of 0.0135 pence per share on 16 September 2021.

 

- Ends -

 

 Enquiries:

 Nuformix plc

+44 (0) 1223 627 222

Dr Anne Brindley, CEO

Allenby Capital Limited

+44 (0) 20 3328 5656

Nick Athanas / George Payne (Corporate Finance)

Stefano Aquilino / Matt Butlin (Sales & Corporate Broking)

Walbrook PR

Anna Dunphy / Paul McManus

+44 (0) 20 7933 8780nuformix@walbrookpr.com

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Dr Alastair Riddell

2

 

Reason for the notification

 

a)

 

Position/status

 

PDMR - Chairman

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Nuformix plc

b)

 

LEI

 

2138003XG3H3I2J3BJ24

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of nominal value 0.1 pence each

 

 

GB00BYW79Y38

b)

 

Nature of the transaction

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

Price(s)

 

Volume(s)

0.0135p

 

350,000

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

- Total

 

 

350,000

 

0.0135p

 

£4,725.00

e)

 

Date of the transaction

 

16 September 2021

f)

 

Place of the transaction

 

London Stock Exchange, Main Market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGPUACBUPGGGQ
Date   Source Headline
1st Feb 20227:00 amRNSAdviser Appointments
31st Jan 20222:09 pmRNSDirector/PDMR Shareholding
31st Jan 202211:05 amRNSResult of General Meeting
17th Jan 20229:56 amRNSPosting of Circular and Notice of General Meeting
10th Jan 20224:23 pmRNSDirector/PDMR Shareholding
21st Dec 20217:00 amRNSHolding(s) in Company
14th Dec 20212:05 pmRNSSecond Price Monitoring Extn
14th Dec 20212:00 pmRNSPrice Monitoring Extension
14th Dec 20217:01 amRNSSubscription to raise £1.65 million
14th Dec 20217:00 amRNSHalf year Report
25th Nov 20217:00 amRNSPositive pre-clinical data on NXP002
17th Nov 20219:34 amRNSHolding(s) in Company
12th Nov 20217:00 amRNSNXP004 patent application filing
9th Nov 20217:00 amRNSDirectorate Change
4th Oct 20212:01 pmRNSPrice Monitoring Extension
16th Sep 20212:14 pmRNSDirector/PDMR Shareholding - Replacement
16th Sep 202112:47 pmRNSDirector/PDMR Shareholding
13th Sep 20217:00 amRNSLicensing agreement with Oxilio for NXP001
24th Aug 202111:57 amRNSResult of AGM
23rd Jul 20211:35 pmRNSPosting of Annual Report and Notice of AGM
22nd Jul 20217:00 amRNSLetter to shareholders re: Dr Anne Brindley
21st Jul 20214:41 pmRNSSecond Price Monitoring Extn
21st Jul 20214:36 pmRNSPrice Monitoring Extension
21st Jul 20217:00 amRNSDirectorate Change
15th Jul 20217:00 amRNSFinal results for the year ended 31 March 2021
10th Jun 20219:25 amRNSHolding(s) in Company
7th Jun 20217:00 amRNSNotice of Allowance of Patent in US
1st Jun 20217:00 amRNSProject update - Progress on NXP002 and NXP004
24th May 20217:00 amRNSDirectorate Changes
12th May 202111:35 amRNSHolding(s) in Company
11th May 20211:51 pmRNSHolding(s) in Company
22nd Apr 20212:06 pmRNSSecond Price Monitoring Extn
22nd Apr 20212:00 pmRNSPrice Monitoring Extension
8th Apr 20213:30 pmRNSCorrection: Holding(s) in Company
8th Apr 202111:54 amRNSHolding(s) in Company
6th Apr 202110:38 amRNSHolding(s) in Company
30th Mar 20215:14 pmRNSHolding(s) in Company
29th Mar 202111:27 amRNSResult of General Meeting and Total Voting Rights
22nd Mar 20217:00 amRNSNXP001 (Oncology) - Exercise of Option by Oxilio
19th Mar 20214:41 pmRNSSecond Price Monitoring Extn
19th Mar 20214:36 pmRNSPrice Monitoring Extension
19th Mar 202111:05 amRNSSecond Price Monitoring Extn
19th Mar 202111:00 amRNSPrice Monitoring Extension
19th Mar 20219:05 amRNSSecond Price Monitoring Extn
19th Mar 20219:00 amRNSPrice Monitoring Extension
11th Mar 20217:00 amRNSInitiation of research by Allenby Capital
10th Mar 202111:05 amRNSSecond Price Monitoring Extn
10th Mar 202111:00 amRNSPrice Monitoring Extension
10th Mar 20219:05 amRNSSecond Price Monitoring Extn
10th Mar 20219:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.